Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288295 | PMC |
| http://dx.doi.org/10.1297/cpe.2023-0011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual Role of DLK1 in GnRH Neuron Ontogeny.
Stem Cell Rev Rep
September 2025
Stem Cells and Metabolism Research Program (STEMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki, 00014, Finland.
Mutations in Delta Like Non-Canonical Notch Ligand 1 (DLK1), a paternally expressed imprinted gene, underlie central precocious puberty (CPP), yet the mechanism remains unclear. To test the hypothesis that DLK1 plays a role in gonadotropin releasing hormone (GnRH) neuron ontogeny, 75 base pairs were deleted in both alleles of DLK1 exon 3 with CRISPR-Cas9 in human pluripotent stem cells (hPSCs). This line, exhibiting More than 80% loss of DLK1 protein, was differentiated into GnRH neurons by dual SMAD inhibition (dSMADi), FGF8 treatment and Notch inhibition, as previously described, however, it did not exhibit accelerated GNRH1 expression.
View Article and Find Full Text PDFA single blood luteinizing hormone level of triptorelin stimulation test can diagnose hypothalamic-pituitary-gonadal axis activation in girls with high body mass index.
Front Pediatr
August 2025
Department of Pediatrics, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu, China.
Background: Body mass index (BMI) may influence peak luteinizing hormone (PLH) levels during gonadotropin releasing hormone (GnRH) or GnRH analogues stimulation testing. BMI effects should be considered when interpreting test results for pubertal disorders in girls with overweight/obesity, but few studies have excluded it.
Methods: This was a hospital data-based retrospective study.
Attribute preferences associated with gonadotropin-releasing hormone agonists/antagonists among women with endometriosis in the United States.
Womens Health (Lond)
September 2025
Worldwide Medical and Safety, Pfizer Inc, New York, NY, USA.
Background: Endometriosis symptoms have multifaceted manifestations, and there are few approved nonsurgical treatment options. Gonadotropin-releasing hormone (GnRH) agonists/antagonists for endometriosis vary on efficacy, safety profile, and out-of-pocket (OOP) cost, among other features.
Objectives: This study quantified the importance that women with endometriosis in the United States (US) placed on pain and non-pain features that differ among these medications.
A retrospective comparison of live birth rate in freeze-all cycles between progestin-primed ovarian stimulation with dydrogesterone and GnRH antagonist protocols.
Eur J Obstet Gynecol Reprod Biol
September 2025
Department of Obstetrics and Gynaecology, University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam.
Research Question: Does progestin-primed ovarian stimulation (PPOS) using dydrogesterone yield a live birth rate comparable with the gonadotrophin-releasing hormone (GnRH) antagonist protocol in in-vitro fertilization (IVF) freeze-all cycles?
Design: This retrospective cohort study, conducted at a tertiary hospital from June 2022 to January 2024, included 1045 women aged 18-40 years undergoing IVF/intracytoplasmic sperm injection with freeze-all indications. Participants were assigned to receive PPOS-dydrogesterone (n = 482) or GnRH antagonist (n = 563), followed by frozen embryo transfer (FET). The primary outcome was the live birth rate after the first FET cycle.
A semi-mechanistic mathematical framework for simulating multi-hormone dynamics in reproductive endocrinology.
Comput Struct Biotechnol J
August 2025
Department of Obstetrics, Gynecology and Reproductive Medicine, Foch Hospital, Suresnes, France.
Background: The dynamic interplay of ovarian hormones is central to reproductive physiology, yet the complexity of their cyclic variations poses challenges for analysis, simulation, and teaching. This study presents a framework for generating physiologically constrained, multi-hormone synthetic time series that capture intra- and inter-individual variability across phenotypes.
Methods: We developed a semi-mechanistic mathematical framework to generate synthetic multi-hormone profiles (estradiol, FSH, LH, AMH, testosterone, GnRH) using parametric equations embedding known physiological feedbacks (e.